Bulletin de l'Académie Nationale de Médecine | VOL. 206

Propriété industrielle et recherche fondamentale dans la genèse du vaccin ARNm contre la COVID-19

Publication Date Dec 1, 2022


The extreme speed of the design and provisional approval of the covid-19mRNA vaccines, as well as the speed of their mass production one year after the start of the pandemic, surprised and contradicted all the experts and big pharmaceutical companies who expected years of development. Their superior efficacy to other vaccines should make mRNA vaccines indispensable, but their diffusion remains low outside developed countries. Several reasons are given, ranging from logistical difficulties to mistrust of populations or the impossibility of producing them locally without lifting patents. Considering that, in these debates, these patents may be challenged because they do not meet the necessary criteria of inventiveness, it appeared necessary to review the history, over more than three decades, of the academic research and entrepreneurial spirit that led to the advent of mRNA platforms, to examine their mutual merits and the role of industrial property for biotechnology companies.


Big Pharmaceutical Companies Entrepreneurial Spirit Mass Production Approval Of Vaccines Big Companies Design Of Vaccines Provisional Approval mRNA Vaccines Extreme Speed Industrial Property

Round-ups are the summaries of handpicked papers around trending topics published every week. These would enable you to scan through a collection of papers and decide if the paper is relevant to you before actually investing time into reading it.

Climate change Research Articles published between Jan 23, 2023 to Jan 29, 2023

R DiscoveryJan 30, 2023
R DiscoveryArticles Included:  3

Climate change adaptation has shifted from a single-dimension to an integrative approach that aligns with vulnerability and resilience concepts. Adapt...

Read More

Coronavirus Pandemic

You can also read COVID related content on R COVID-19

R ProductsCOVID-19


Creating the world’s largest AI-driven & human-curated collection of research, news, expert recommendations and educational resources on COVID-19

COVID-19 Dashboard

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on “as is” basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The Copyright Law.